伊瓦布拉丁在心力衰竭和超越心脏衰竭中的生理影响
Audra N Iness1, Keyur M Shah2, Rakesh C Kukreja3
1Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA.
Molecular and cellular biochemistry
|September 28, 2023
概括
伊瓦布拉丁可以选择性地抑制心率的可笑电流. 虽然尚未证明它可以降低心力衰竭的死亡率,但其其他效应可能有利于高上腺素状态和COVID-19并发症.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊瓦布拉丁向鼻腔节点的奇怪电流,调节心率.
- 它在心力衰竭中的使用正在被探索,因为它可以降低心肌的氧气需求和改善腹填充等益处.
- 对于心力衰竭的绝对死亡率益处仍然没有得到证实.
研究的目的:
- 审查关于伊瓦布拉丁在心力衰竭中的疗效的临床试验.
- 探索艾瓦布拉丁除了降低心率之外,还有什么益生菌效应.
- 研究在高上腺体状态和COVID-19并发症中的潜在应用.
主要方法:
- 关键临床试验的审查.
- 对药理效应和临床结果的分析.
- 基于现有数据,探索潜在的治疗应用.
主要成果:
- 伊瓦布拉丁通过抑制有趣的电流来降低心率.
- 临床试验表明,在心力衰竭中具有潜在的益处,但缺乏明确的死亡率降低.
- 伊瓦布拉丁会影响氨酸- ангиотензин-阿尔多斯特系统,交感激活和内皮功能.
结论:
- 伊瓦布拉丁是一种心率降低剂,在心力衰竭中具有潜在的益处.
- 它的类效应需要进一步研究,以获得更广泛的临床应用.
- 潜在的用途包括管理高上腺体状况和减轻COVID-19相关问题.
相关概念视频
Heart Failure Drugs: β-Blockers
357
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
357
Heart Failure Drugs: Inotropic Agents
611
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
611
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management
12
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
12
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14


